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Introduction: Pharmacostatistical models can quantify different 
relationships and improve decision making in personalized medi-
cine and drug development. Our objectives were to develop models 
describing non–small-cell lung cancer (NSCLC) dynamics during 
first-line treatment with erlotinib, and survival of the cohort.
Methods: Data from patients with advanced NSCLC (n = 39) 
treated first-line with erlotinib (150 mg/day) were analyzed using 
nonlinear mixed effects modeling. Exposure-driven disease-drug 
models were built to describe tumor metabolic and proliferative 
dynamics evaluated by positron emission tomography (PET) using 
2′-deoxy-2′-[18F]fluoro-D-glucose (FDG) and 3′-[18F]fluoro-3′-
deoxy-L-thymidine (FLT), respectively, at baseline, weeks 1 and 6 
after starting erlotinib treatment. A parametric time-to-event model 
was built to describe overall survival (OS). Demographics, histol-
ogy, mutational, smoking, and baseline performance statuses were 
tested for their effects on models developed, in addition to tumor 
dynamics on survival.
Results: An exponential relationship described progression, and a con-
centration-driven drug effect model described erlotinib effect. An acti-
vating epidermal growth factor receptor (EGFR) mutation increased 
the drug effect as assessed using FDG-PET by 2.19-fold (95% confi-
dence interval [CI]:1.35–4.44). An exponential distribution described 
the times-to-death distribution. Baseline FDG uptake (p=0.0005; haz-
ard ratio [HR] =1.26 for every unit increase, 95%CI: 1.13–1.42) and 
relative change in FDG uptake after 1 week of treatment (p=0.0073; 
HR=0.84 for every 10% drop, 95%CI: 0.71–0.91) were significant OS 
predictors irrespective of the EGFR mutational status. FLT-PET was 
statistically less significant than FDG-PET for OS prediction.
Conclusion: Models describing tumor dynamics and survival of 
advanced NSCLC patients first-treated with erlotinib were devel-
oped. The impacts of different covariates were quantified.
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(J Thorac Oncol. 2015;10: 84–92)
Lung cancer is the most commonly diagnosed cancer and the primary cause of cancer related mortality.1 Non–small-cell 
lung cancer (NSCLC) accounts for approximately 85% of the 
lung cancer cases.2 Despite the high medical needs, effective 
treatments available for advanced NSCLC are limited and the 
process of introducing new ones is inefficient.3 Modeling and 
simulation have been endorsed among other tools to stream-
line drug development and therapy.4–6 Nevertheless, a limited 
number of models have been developed for NSCLC.7
Pharmacostatistical NSCLC models have mostly used 
tumor size changes as an endpoint for response evaluation, 
or as a survival predictor.8,9 However, evaluating the response 
of solid tumors to newer anticancer therapies using anatomi-
cal size-based assessments has been recently questioned 
since these therapies act by mechanisms unlikely to result in 
tumor shrinkage, and may prolong survival without tumor 
regression.10,11 Therefore, evaluating the functional activity of 
tumors by positron emission tomography (PET) was recently 
promoted.12 PET has demonstrated its usefulness in inform-
ing therapeutic decisions, and progressively took a crucial 
role in personalized cancer management. Similarly, using 
PET has a promising potential for decision making in anti-
cancer drug development, an area where there is still a limited 
use of PET.12 However, responses measured using PET are 
commonly categorized (progressive metabolic disease, stable 
metabolic disease, partial metabolic response, and complete 
metabolic response),12,13 which can potentially discard infor-
mation and reduce the statistical power of analysis similar to 
other categorical scales, and as a result the use of continuous 
scales was recommended.14,15 Modeling offers a great oppor-
tunity to efficiently utilize continuous metrics either as end-
points or as covariates to investigate and quantify their effects 
on desired outcomes.
Several radionuclides have been used to evaluate the 
response of cancerous lesions to antineoplastic therapeutics 
using PET. 2′-deoxy-2′-[18F]fluoro-D-glucose (FDG), a glu-
cose analogue indicating the metabolic activity of the tissue, 
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has been the most commonly used tracer.16 3′-[18F]fluoro-3′-
deoxy-L-thymidine (FLT), a thymidine nucleoside analogue 
giving a direct measure of the proliferative activity, has also 
been used.17 A recent phase-II study by Zander et al.18 evalu-
ated and compared the accuracy of PET using FDG and FLT 
in early predicting nonprogression and survival in advanced 
NSCLC patients treated first-line with erlotinib, a tyrosine 
kinase inhibitor (TKI) acting on the epidermal growth factor 
receptor (EGFR). They found that an early metabolic response 
(≥30% reduction in FDG uptake) as measured using FDG-
PET after 1 week of therapy was predictive of both nonpro-
gression according to RECIST 1.0 (Response Evaluation 
Criteria in Solid Tumors)19 after 6 weeks of therapy, and of 
overall survival (OS). An early response as measured by FLT-
PET did not predict either.
Based on data from this trial, our first objective was to 
develop pharmacokinetic/pharmacodynamic models linking 
erlotinib exposure to the time courses of the dynamics of the 
tumors as assessed by FDG and FLT uptakes measured on a 
continuous scale in patients with advanced NSCLC treated 
first-line with erlotinib. Different covariate relationships 
which could affect the uptakes were evaluated and quantified. 
Second, we aimed to describe the times-to-death distribution 
of the cohort, and to evaluate different factors as OS predic-
tors, among which are the tumor dynamics. Such models 
may possibly be used for simulations and informing decision 
making.20
PATIENTS AND METHODS
Patients, Data, and PET-imaging
Data were available from Zander et al.18 (NCT00568841). 
Briefly, 40 patients with previously untreated stage-IV 
NSCLC were recruited for this phase-II study conducted at 
the University Hospital of Cologne, Germany. All patients 
gave written informed consents, and the study was approved 
by the local ethics committee and all other competent authori-
ties. Patients were first-line treated with erlotinib at an oral 
dose of 150 mg once daily until progression or unacceptable 
toxicity. The dosage was reduced or suspended if a patient was 
intolerant to adverse reactions. Three FDG and FLT-PET scans 
were scheduled; (i) at baseline within 10 days before starting 
erlotinib (range of actual time relative to treatment initiation 
on which PET scans were made; FDG: -8 to 0 days; FLT: -9 
to 0 days), (ii) 1 week (FDG: 6–12 days; FLT: 5–14 days), and 
(iii) 6 weeks (FDG: 41–53 days; FLT: 40–61 days) after start-
ing therapy. The uptakes of FDG (101 observations) and FLT 
(99 observations), covariates, and OS data from 39 patients 
were used for analysis (one patient was excluded from analy-
sis since he was irradiated within the first 6 weeks). Zander et 
al. excluded five more patients in their analysis; three patients 
died before any follow-up scans, and two patients had the 
treatment suspended for more than 2 weeks owing to toxicity. 
Patient characteristics are presented in Table 1.
FDG and FLT were synthesized as previously 
described.21,22 An ECAT EXACT 47 scanner (Siemens, 
Erlangen, Germany) was used for obtaining PET images from 
the patients who had been fasting for at least 6 hours. Time 
intervals between tracer injection (doses on average, 365 ± 30 
MBq of FDG and 305 ± 89 MBq of FLT) and image acquisi-
tion were 59 ± 14 (standard deviation) and 58 ± 15 minutes for 
FDG and FLT, respectively. Blood glucose measured before 
FDG-PET scanning was 123 ± 22 mg/dL. The attenuation-cor-
rected scan trajectory covered 90 cm (6 bed positions: 5-min 
emission, 3-min transmission).
Scans were normalized to body mass, corrected for 
decay, dead time, scatter, and random coincidences, and 
reconstructed using ordered-subset expectation maximiza-
tion. The same scanner, same acquisition protocol, and same 
reconstruction software were used for all patients on all visits. 
The standardized uptake value peak (SUV
peak
) was estimated 
for each lesion using a 1.2-cm diameter fixed sized circle 
centered around the tumor area with the highest uptake. Five 
or fewer lesions having the highest SUVs (primary tumor or 
metastases) were selected and the SUV
peak
 of the hottest lesion 
at each time point, not necessarily the same lesion, served as 
the pharmacodynamic endpoint for model development.
Data Analysis, Software, and 
Model Selection Criteria
Nonlinear mixed effects modeling was used for analy-
sis, and data were fitted to the models using NONMEM soft-
ware (version 7.2).23 The objective function value (OFV), a 
goodness-of-fit statistic computed by NONMEM, was used in 
discriminating between nested models (the lower the OFV, the 
better the fit). ΔOFV follows approximately a chi-squared dis-
tribution, and therefore a decrease of at least 3.84 points in the 
OFV for one degree of freedom was considered statistically 
significant (p≤0.05) for model discrimination. For covariate 
analyses, all covariate relationships were tested one at a time, 
and the relationship giving the biggest OFV drop was included 
in the model each step, provided that the drop was at least 3.84 
points. This was repeated for the rest of the covariates until no 
significant drops in the OFV resulted.
Goodness-of-fit plots, bootstrap analyses, and visual 
predictive checks using R (versions 2.15.2 and higher),24 
Xpose4 (version 4.4.0),25 Perl Speaks NONMEM (versions 
3.5.3 and higher),26 &/or Pirana (versions 2.8.2 and higher)27 
programs were used to assist model development.
Pharmacokinetic/Pharmacodynamic Model
Model development
No erlotinib concentrations were measured in the study, 
and therefore to drive the pharmacodynamic model, a pub-
lished one-compartment pharmacokinetic model for erlo-
tinib28 was used to generate the individual pharmacokinetic 
parameters and plasma concentrations based on the individual 
set of covariates as identified by the pharmacokinetic model. It 
needs to be mentioned that α
1
-acid glycoprotein (AAG) levels, 
identified among the significant covariates and found to result 
in approximately a 7.5% decrease in erlotinib clearance for 
every 10% increase in AAG levels, was not measured in the 
study. However, as AAG and erlotinib concentrations increase, 
the unbound fraction of erlotinib was expected not to change 
significantly, and only a modest effect on pharmacodynamics 
was speculated to result.28
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A tumor progression inhibition model29 was used to 
describe the functional dynamics of the lesions represented 
by the FDG or FLT uptakes. The model accounts for both the 
natural tumor progression and the inhibitory effect of erlo-
tinib (Figure 1). A component accounting for a decline in 
drug effect with time was also included. Both exponential 
and Gompertzian30 models were tested to account for tumor 
progression. Exponential and Weibull models were tested to 
describe the waning of erlotinib effect with time.
To account for individual deviations from the typical 
population parameters, inter-individual variability was incor-
porated as random effects. A variance–covariance matrix was 
estimated from which the inter-individual variability vari-
ances, and the covariances between the inter-individual effects 
can be determined. Additive and exponential stochastic mod-
els to describe inter-individual variability (assuming normal 
and log-normal distributions, respectively) were tested on 
all parameters. Additive, proportional, power, and combined 
(additive+proportional) residual error models were tested to 
describe measurement error and other residual unexplained 
sources of variability.
Covariates including the mutational status (presence 
or absence of an activating mutation in the kinase domain 
of EGFR), NSCLC histological sub-classification, smoking 
status, and demographics were tested for their influence on 
pharmacodynamics. It needs to be mentioned that the EGFR 
mutational status was not determined for eight patients due 
to lack of enough tumor tissue material, and therefore these 
patients were excluded from the covariate analysis. It needs 
also to be mentioned that patients with no information on 
the EGFR mutational status were previously assumed not 
to have an activating EGFR mutation based on their clinical 
responses.18,31 To test this assumption, we reincluded these 
patients and reestimated the parameters for comparison with 
the estimates based on the reduced dataset.
The pharmacokinetic/pharmacodynamic model param-
eters were estimated using the first-order conditional estima-
tion (FOCE) method with interaction between inter-individual 
variability and residual error.
Model evaluation
The assumption of normality of the observations made 
using the maximum likelihood approach implemented in the 
FOCE method was tested by inspecting the quantile–quantile 
plots of the conditional weighted residuals (CWRES) against 
theoretical standard normal quantiles. Model misspecifica-
tions were evaluated by inspecting conditional weighted resid-
uals against population predictions and time.
Model robustness, precision, and bias of parameter esti-
mates were assessed using bootstrap analysis. Based on the 
original dataset, 1000 replicate datasets were generated by sam-
pling individuals with replacement, and the model was refitted 
TABLE 1.  Patient Characteristics
Characteristic n (%)
Age (years)
  Median (range) 62 (38–78)
Gender
  Males
  Females
18 (46.2%)
21 (53.8%)
Baseline ECOG performance status
  0
  1
  2
17 (43.6%)
16 (41.0%)
6 (15.4%)
Histological subclassification
  Adenocarcinoma
  Bronchoalveolar carcinoma
  Squamous cell carcinoma
  Large cell carcinoma
28 (71.8%)
4 (10.2%)
6 (15.4%)
1 (2.6%)
EGFR mutational status
  Negative
  Positive
  Not determined
24 (61.5%)
7 (17.9%)
8 (20.6%)
Smoking status
  Non-smoker (0.0 pack-years)
  Previous light smoker (0.1–10 pack-years)
  Previous heavy smoker (>10 pack-years)
  Current smoker
  No data available
14 (35.9%)
4 (10.2%)
5 (12.8%)
13 (33.4%)
3 (7.7%)
Brain metastasis
  Yes
  No
13 (33.3%)
26 (66.7%)
FDG SUV
peak
a
  Baseline observations (median, range)
  Week 1 observations (median, range)
  Week 6 observations (median, range)
39 (6.3, 1.8–14.1)
36 (5.2, 1.7–12.7)
26 (5.0, 1.4–11.4)
FLT SUV
peak
a
  Baseline observations (median, range)
  Week 1 observations (median, range)
  Week 6 observations (median, range)
39 (3.1, 1.0–7.3)
35 (2.9, 0.7–7.5)
25 (2.4, 0.6–7.2)
Survival
  Died
  Lost to follow-up (right censored)
  Overall survival/daysb, medianc (range)
37 (94.8%)
2 (5.2%)
164 (0–1626)
aDifferent number of observation between FDG-PET and FLT-PET are due to two 
patients showing up for one of the scheduled FDG-PET scans but not for the FLT-PET 
scans which took place on separate days.
bOverall survival was defined as the length of time the patients lived after starting 
erlotinib therapy.
cBased on Kaplan–Meier estimate.
ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor 
receptor; FDG, fluorodeoxy-D-glucose; FLT, fluorodeoxy-L-thymidine; SUV
peak
, 
standardized uptake value peak. 
FIGURE 1.  A schematic representation of the 
tumor progression inhibition model used for phar-
macokinetic/pharmacodynamic modeling. SUV, 
standardized uptake value.
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to the replicates. The medians of the parameter estimates were 
determined and the corresponding nonparametric 95% confi-
dence intervals were constructed. The predictive power of the 
model was evaluated using a visual predictive check. 1000 data-
sets were created and the SUV
peak
 measurements were simulated 
based on the models developed. 95% confidence intervals of the 
median, fifth and ninety-fifth percentiles of the simulated data 
representing the 90% prediction intervals were plotted. The plot 
was then overlaid with the real observations for comparison.
Survival Analysis
Model development
A landmark survival analysis was performed with the 
landmark time point chosen as the PET scan scheduled after 1 
week of treatment with erlotinib, and therefore 36 patients out 
of 39 were included in the analysis after excluding the patients 
who died before having an SUV
peak
 measurement on week 1. A 
fully parametric regression time-to-death model which allows 
for simulations at later stages was developed to describe the 
OS of the patients, where the individual times-to-death are 
assumed to follow a continuous distribution. We parameter-
ized this distribution in terms of the hazard rate, h(t), which 
is the instantaneous hazard of dying at each time point pro-
vided that the patient lives to that point. The hazard function 
was expressed as the product of a baseline hazard, h
0
(t), which 
specifies how the hazard function changes with time, and a 
second function characterizing how the hazard varies as a 
function of patient covariates as shown (equation 1):
h t h t x x xn n( ) = ( ) + +…+( )* eo * * *β β β1 1 2 2  (eq. 1)
where x
1
, x
2
, …, x
n
 represent a set of n predictors whose impacts 
are quantified by the size of their respective regression coef-
ficients β
1
, β
2
, …, β
n
. For a comprehensive understanding of 
survival analysis and its implementation in pharmacostatisti-
cal modeling we would like to refer the reader to a recently 
published tutorial.32
Different baseline hazard functions corresponding to 
exponential, Weibull, Gompertz, log-logistic and log-normal 
distributions were tested for the best description of the times-
to-death distribution.
Different covariates including the Eastern Cooperative 
Oncology Group (ECOG) performance status evaluated at 
baseline, smoking, EGFR mutational status, histological 
sub-classification, the presence of a brain metastasis, demo-
graphics, and FDG-PET and FLT-PET-related parameters 
including baseline SUV
peak
 centered around the median (i.e. 
baseline SUV
peak
–median baseline SUV
peak
 for all patients), 
and the relative change in SUV
peak
 after 1 week of treatment 
were evaluated as OS predictors. For covariates with missing 
data (mutational and smoking statuses), patients with missing 
information were excluded and a separate stepwise covariate 
analysis was conducted for the respective set of patients.
Covariates related to FDG and FLT (i.e. baseline 
SUV
peak
 and SUV
peak
 relative changes) were tested separately 
in different survival models. The relative change after 1 week 
of treatment was calculated as follows (equation 2)
Relative change
in SUV
baseline SUV SUV after
peak
peak peak=
− 1 week of treatment
baseline SUVpeak
 (eq. 2)
Model evaluation.
A bootstrap (1000 samples) evaluating the model stability 
and precision of the parameter estimates, and a visual predic-
tive check (1000 datasets) simulating the times-to-death of the 
patients to evaluate the predictive power of the model were per-
formed. Furthermore, residual-based diagnostics were performed 
to test the overall model adequacy (Cox–Snell residuals) and the 
functional form of the included covariates (Martingale residu-
als) (presented in the supplementary document, Supplemental 
Digital Content, http://links.lww.com/JTO/A688).
Finally, a classic semiparametric Cox proportional haz-
ards model which does not depend on baseline hazard rate 
specification was ran for comparison with the results from the 
fully parametric model.
RESULTS
Pharmacokinetic/Pharmacodynamic Models
FDG model
(i) Model development: An exponential model best 
described the natural progression of the tumor metabolic 
activities. The inhibitory effect of erlotinib on tumor pro-
gression was found to decrease exponentially with time. The 
framework accounting for the change of the metabolic activity 
with respect to time (dSUV
peak
(t)/dt) of the lesions treated with 
erlotinib as represented by the FDG uptake can be represented 
as follows (equation 3; parameter estimates found in Table 2)
dSUV
dt
SUV Cp( )*SUVpeak P peak D
*TAD
peak
( )
* ( ) * * ( )
t
K t K t t= − −e λ
 (eq. 3)
SUV BASE,peak ( )0 =
where K
P
 is the progression rate constant, SUV
peak
(t) is the 
SUV
peak
 at time t, K
D
 is a constant representing the maximum 
drug effect observed after the first dose of erlotinib, λ is a first-
order rate constant for waning of the drug effect, TAD is the 
time after the first erlotinib dose, Cp(t) is the plasma concen-
tration of erlotinib predicted by the pharmacokinetic model, 
and BASE is the estimated baseline SUV
peak
.
Exponential stochastic models were found to adequately 
describe the inter-individual variabilities of baseline SUV
peak
 
and progression rate constant. Accounting for inter-individual 
variabilities of other parameters resulted in imprecise esti-
mates and model instability, and therefore were not included. 
A covariance estimated between baseline SUV
peak
 and the pro-
gression rate constant significantly improved the model fit, 
and unexplained residual variability was best described using 
a proportional error model.
Among the covariate relationships tested, two signifi-
cant relationships were identified; first, the presence of an 
activating EGFR mutation sensitized the patients to erlotinib 
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as it increased the drug effect constant (K
D
) by 2.2-fold; sec-
ond, patients harboring an activating EGFR mutation present 
with SUV
peak
 baselines 38% less compared to their peers with 
no EGFR mutation. Both relationships were parameterized as 
shown in equation 4
θ θ θ= +x * *EGFREGFR( )1  (eq. 4)
where θ is the typical parameter value after accounting for the 
covariate, θ
x
 is a coefficient constant for either K
D
 or BASE, 
θ
EGFR
 is a regression coefficient estimated for the dichotomous 
EGFR status covariate for each relationship tested, and EGFR 
is dichotomous (0 indicating no activating EGFR mutation, 
and 1 indicating its presence).
As previously described, patients with missing EGFR 
mutational status information (n = 8) who were primarily omit-
ted when testing EGFR as a covariate were later reincluded after 
assuming they had no mutation and the analysis was repeated. 
Parameter estimates were found to be similar as patients harbor-
ing an activating EGFR mutation were found to be sensitized 
to the drug effect by a 2.5-fold increase and present with a 
baseline SUV lower by 39%. (ii) Model evaluation: Figure S1 
(Supplementary Digital Content, http://links.lww.com/JTO/
A688 ) verifies the assumption of normality of the observations 
made during estimation, and Figure S2 (Supplementary Digital 
Content, http://links.lww.com/JTO/A688 ) showed no model 
misspecifications. Medians of the parameter estimates and their 
respective 95% confidence intervals generated by bootstrapping 
are listed in Table 2. Median bootstrap values were close to the 
values estimated from the original dataset (indicating a small 
bias), and parameters were estimated with adequate precision.
The predictive performance of the FDG model (evalu-
ated using the visual predictive check) was proven to be ade-
quate since the simulated data (shaded areas) was capable of 
adequately capturing the time course of the observed uptake 
values (black solid and dashed lines) (Fig. 2).
FLT model
(i) Model development: The framework describing the 
proliferative dynamics of the lesions assessed using FLT was 
TABLE 2.  Parameter Estimates (and 95% Confidence Intervals Based on a Bootstrapping Analysis with 1000 Samples) for the 
18F-Flurordeoxyglucose (FDG), 18F-Fluorodexoythmidine (FLT) Pharmacokinetic/Pharmacodynamic Models and the Survival 
Model
Parameter (unit)
Bootstrap Median  
(95%CI)a; n = 31
Bootstrap Median  
(95%CI)b; n = 39
FDG model
  BASE; estimated baseline SUV
peak
6.25 (5.11–7.62) 6.41 (5.33–7.50)
  K
P
; progression rate constant (day−1) 0.00242 (0.000410–0.00758) 0.00315 (0.000288–0.00821)
  K
D
; drug effect constant (mg−1L) 0.0271 (0.0134–0.0463) 0.0226 (0.00893–0.0422)
  λ; rate constant for waning of drug effect (day−1) 0.106 (0.0758–0.177) 0.0993 (0.0687–0.163)
  θ
EGFR,KD
; activating EGFR mutation on K
D
1.19 (0.35–3.44) 1.51 (0.455–5.33)
  θ
EGFR,BASE
; activating EGFR mutation on BASE −0.378 (−0.598 to 0.0534) −0.385 (−0.602 to 0.00703)
  %IIV; interindividual variability (BASE)c 51.3 (36.0–64.9) 48.0 (34.6–60.8)
  %IIV; interindividual variability (K
P
)c 195 (66.0–883) 152 (60.0–643)
  Correlation coefficient (BASE,KP) −0.371 (−0.683 to −0.103) −0.422 (−0.73 to −0.131)
  σ2; variance for the residual error 0.0166 (0.0103–0.0236) 0.0301 (0.0138–0.0564)
FLT model
  BASE; estimated baseline SUV
peak
3.39 (2.75–4.09) 3.34 (2.85–3.88)
  K
P
; progression rate constant (day-1) 0.00845 (0.000381–0.0183) 0.00876 (0.00211–0.0164)
  K
D
; drug effect constant (mg−1L) 0.0327 (0.0118–0.0625) 0.0318 (0.0131–0.0542)
  λ; rate constant for waning of drug effect (day−1) 0.0573 (0.021–0.126) 0.0590 (0.0256–0.126)
  θ
EGFR,BASE
; activating EGFR mutation on BASE −0.396 (−0.621 to −0.0735) −0.461 (−0.651 to −0.189)
  %IIV; interindividual variability (BASE)c 46.3 (33.9–58.8) 47.0 (35.8–57.5)
  %IIV; interindividual variability (K
P
)c 64.5 (0.0199–588) 59.0 (18.8–174.5)
  Correlation coefficient (BASE, K
P
) Not statistically significant for inclusion −0.569 (−0.877 to 0.0313)
  σ2; variance for the residual error 0.0340 (0.0194–0.0543) 0.0340 (0.0213–0.0485)
Survival model; n = 36
  h
0
; hazard constant (day−1) 0.00381 (0.00285–0.00516)
  Hazard ratio for every unit increase in baseline SUV
peak
d 1.26 (1.13–1.42)
  Hazard ratio for every 10% drop in SUV
peak
 after 1 week of treatment 0.841 (0.714–0.907)
aEstimates based on patients with known EGFR mutational status (complete case analysis; n = 31).
bEstimates based on all patients (n = 39).
cInterindividual variability reported as % coefficient of variation assuming log-normal distribution and computed by (exp(ω2) − 1)0.5*100, where ω2 is the estimate of the variance 
of the logarithm of the respective population parameter.
dCentered at the median FDG SUV
peak
 measured for the recruited patients, 6.3.
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similar to that of FDG (equation 3). Exponential stochastic mod-
els described the inter-individual variabilities of baseline SUV
peak
 
and the progression rate constant; it was also not possible to 
account for inter-individual variabilities on other parameters. A 
proportional error model described the residual variability.
Similar to FDG, patients with an activating EGFR muta-
tion were found to present with a baseline FLT SUV
peak
 approx-
imately 40% lower than others. However, accounting for the 
effect of an activating EGFR mutation on the drug effect con-
stant did not improve the fit significantly. (ii) Model evaluation: 
The normality assumption of the observations was verified 
(Figure S1, Supplementary Digital Content, http://links.lww.
com/JTO/A688), and no model misspecifications were evident 
(Figure S2, Supplementary Digital Content, http://links.lww.
com/JTO/A688). FLT model parameter estimates and their 
respective 95% confidence intervals are listed in Table 2. The 
visual predictive check (Fig. 2) has shown the adequate predic-
tive performance of the FLT model except for the ninety-fifth 
percentile of the simulated data where a slight increase in the 
first follow-up scans was not adequately captured.
Survival model
(i) Model development: The exponential distribution (con-
stant baseline hazard) appropriately described the observed sur-
vival times distribution of the cohort. In the covariate analysis, 
the baseline FDG SUV
peak
 and the relative change in the FDG 
SUV
peak
 after 1 week of treatment with erlotinib were found to 
be the most significant OS predictors (p=0.0005 and p=0.0073, 
respectively). A higher FDG SUV
peak
 measured at baseline was 
negatively correlated with OS with a hazard ratio (HR) equal to 
1.26 for every unit increase in the baseline uptake, and in con-
trary, the HR was equal to 0.84 for every 10% drop in the FDG 
SUV
peak
 measured after 1 week of treatment. The inclusion of an 
interaction between both covariates did not improve the model 
fit significantly. Since an exponential distribution was used, the 
HRs can be directly interpreted as time ratios, and therefore 
the HR of 1.26 (baseline uptake) means a median survival time 
shorter by 21% for every unit increase, while the HR of 0.84 
(relative change) means a prolonged median survival time by 
19% for every 10% drop in the FDG SUV
peak
 after 1 week of 
treatment. Figure 3 shows how different baseline FDG SUV
peak
 
and FDG SUV
peak
 relative changes would affect the survival pro-
files (normalized to the median drop in FDG SUV
peak
 at week 1 
[-13.9%] and median baseline FDG SUV
peak
 [6.3], respectively).
Only the relative change in FLT SUV
peak
 after 1 week of 
treatment was significant for inclusion in the FLT-relevant sur-
vival model (baseline FLT SUV
peak
 was not significant), yet the 
significance was lower compared to the FDG-relevant survival 
model. No other covariates improved the model fit. (ii) Model 
evaluation: Model parameters were estimated with low bias 
and adequate precision as evaluated in the bootstrap (Table 2). 
The visual predictive check (Fig. 4) showed that the observed 
Kaplan–Meier curve lied well within the prediction interval 
demonstrating the predictive power of the model. Cox–Snell 
and Martingale residual plots depicted in Figures S3 and S4, 
respectively (Supplementary Digital Content, http://links.
lww.com/JTO/A688), raised no critical concerns.
The semiparametric Cox proportional hazards model 
gave the same conclusions; baseline FDG SUV
peak
 (hazard 
ratio [HR]=1.31 for every unit increase, 95%CI: 1.18–1.43), 
and the relative change in FDG uptake after 1 week of treat-
ment (HR=0.85 for every 10% drop, 95%CI: 0.72–0.98) were 
the significant OS predictors.
FIGURE 2.  Visual predictive checks (1000 samples) for the FDG model (left) and FLT model (right) showing the time courses 
of the observed and simulated data since baseline measurement. Median (solid line), fifth and ninety-fifth percentiles of the 
observed data (dashed lines) are compared to the 95% confidence intervals of the median, fifth and ninety-fifth percentiles of 
the simulated data (shaded regions).
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DISCUSSION
We successfully developed models describing the time 
courses of advanced NSCLC metabolic and proliferative 
dynamics while treated first-line with erlotinib, and quantified 
the effects of an activating epidermal growth factor receptor 
mutation on tumor dynamics. We also described the times-
to-death distribution, and quantified the effects of tumor 
dynamics on prognosis while showing the benefit of metabolic 
activity assessed using FDG-PET as an OS predictor.
The Gompertz model has been commonly used to 
describe the progression of different tumors, including 
NSCLC.8 However, a Gompertzian function has not given a 
better fit in our case in comparison to an exponential model 
(for both FDG and FLT). While exponential progression could 
be valid within the time period for which the data has been 
available (6 weeks), caution needs to be taken if any extrapo-
lations were to be made outside the period tested. One may 
speculate that a lesion would progress until a limit where it 
starts stripping off its nutrients and supplies, and consequently 
the progression would be capped.33 Our model also comes in 
contrast with Wang et al.9 who described NSCLC progression 
using a linear relationship.
Although it is very likely that patients differ in their 
responses to erlotinib and hence there is a need to describe 
inter-individual differences in drug effect-related parameters, 
this was not possible. Fitting a nonlinear model to three obser-
vations for each patient (as planned) is challenging; more-
over, three patients died before having their second scheduled 
scan, and ten others died before their third. This gave a sparse 
dataset where discriminating between different parameters 
was difficult. Despite this, we were successful in quantifying 
the effect of an activating EGFR mutation in the FDG model 
and linked this to erlotinib exposure, which explained some 
of the drug effect variability. This finding came in line with 
FIGURE 3.  Upper panel: survival profile plots 
showing how different starting baseline FDG SUVpeak 
can affect survival according to the developed 
model; the plots are normalized to the median 
drop in FDG SUVpeak at week 1 (-13.9%). Lower 
panel: survival profile plots showing how different 
responses and relative changes in FDG SUVpeak after 
1 week of treatment with erlotinib can affect sur-
vival according to the developed model; the plots 
are normalized to the median baseline SUVpeak (6.3).
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the literature reporting that patients harboring an activating 
EGFR mutation are more likely to benefit from EGFR TKI 
therapy.34,35
In the second part of our analysis, the times-to-death 
distribution was adequately described using an exponential 
distribution. The survival data extended for some years for 
some patients, yet FDG and FLT uptake measurements were 
limited to the first 6 weeks according to the study design. Since 
extrapolation outside the tested period was not possible using 
our pharmacokinetic/pharmacodynamic model as described 
above, model-generated uptake values were not used to simul-
taneously drive the time-to-event model, and uptake-related 
measurements were incorporated as covariates in the survival 
analysis in a sequential stage. Even though we acknowledge 
the economic and logistic burdens associated with perform-
ing PET scans for long periods of time, we believe more 
data collected for longer periods would help in developing a 
more mechanistic model accounting for different underlying 
processes, and thereby allowing extrapolations for different 
purposes.
Baseline tumor metabolic activity measured using FDG-
PET was the strongest OS predictor, where the underlying 
death hazard increases by 26% for every unit increase in the 
baseline uptake of FDG. This conforms to literature report-
ing that the baseline metabolic tumor burden can serve as a 
prognostic measure for NSCLC.31,36 Similar to Zander et al. 
who used conventional statistical analyses,18 our model shows 
that measuring FDG uptake as early as 1 week after treatment 
initiation can provide an early prediction of OS (death hazard 
decreases by approximately 16% for every 10% drop in the 
SUV
peak
 of FDG after 1 week of treatment). This is 7 weeks 
earlier compared to Wang et al.’s model for NSCLC,9 as well 
as Claret et al.’s model for colorectal cancer,29 both of whom 
used changes in tumor size instead. Thus FDG-PET presents 
itself as a promising tool which can early identify patients who 
might benefit from erlotinib treatment irrespective of their 
EGFR mutational status. This could be of high clinical rele-
vance for patients with wild-type EGFR as it has been recently 
reported that a small proportion of patients with no activating 
EGFR mutations can benefit from treatment with erlotinib in 
terms of survival.37 This could also be of relevance for patients 
whose EGFR mutational status is unknown because of some 
technical problems.38
FLT-relevant parameters were statistically less sig-
nificant in predicting OS compared to FDG. This has been 
recently attributed to lower uptake and lower specificity of 
FLT in tumors.39
To the best of our knowledge, this is the first model-
ing framework linking exposure and NSCLC tumor dynam-
ics assessed using PET. We managed to quantify the effect 
of an activating EGFR mutation on tumor dynamics and link 
it to exposure. Moreover we managed to corroborate and 
quantify the evidence for the potential use of FDG-PET in 
early predicting survival in NSCLC, and hence providing ear-
lier answers with regard to the efficacy of novel treatments 
anticipated to possess mechanisms unlikely to result in tumor 
shrinkage. We highly recommend further similar analyses 
and models development, preferably using larger and richer 
databases, to further confirm our findings. Efficiently utilizing 
tumor functional dynamics as an endpoint measured on a con-
tinuous scale, and combining this with survival simulations, 
may provide a powerful tool for streamlining personalized 
treatment and clinical development.
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